Eli Lilly is the first leading pharmaceutical company to provide a GLP-1/GIP dual-action weight-loss and diabetes medication in india with the launch of Mounjaro (Tirzepatide).
Given that obesity and diabetes are major issues in india, Eli Lilly is in a strong position to benefit from the move ahead of competition from rival Novo Nordisk's weight-loss medication Wegovy, which has not yet reached indian shores. With Mounjaro's arrival, millions of people's medical care may change dramatically.
Mounjaro: Pricing And Market Potential
Approved by India's drug regulator, Mounjaro is delivered via a once-weekly injection with two price points:
₹3,500 ($40.54) per vial of 2.5 mg
₹4,375 ($50.67) per vial of 5 mg
At 5 mg, patients should anticipate monthly expenses of approximately ₹16,000 ($200), well less than the U.S. list price of $1,086.37 per month although actual U.S. costs to American patients differ with insurance coverage. Despite its cost-effectiveness, healthcare analysts project strong demand for Mounjaro because of its efficacy in glycemic control as well as in weight loss.
Mechanism of Action
"Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) are two important hormones that Mount Jaro copies," Dr. Manisha Arora, director of Internal Medicine at CK Birla Hospital in Delhi, told The indian Express. The hormones prolong satiety by controlling blood sugar levels, decreasing appetite, and delaying digestion. By acting on both GLP-1 receptors, Mounjaro's dual mechanism may be more effective than Ozempic's (Semaglutide).
Side Effects
In The indian Express, Dr. Arora issued a warning that patients can experience gastrointestinal side effects: "Gastrointestinal issues like nausea, vomiting, diarrhea, and acid reflux are common side effects. Frequent diarrhea can occasionally result in acute renal damage and dehydration. She said that gallbladder-related problems like inflammation and gallstones could be brought on by abrupt weight loss.
Appropriate Patient Profile
According to what Dr. Arora told The indian Express, Mounjaro is recommended for:
Adults with type 2 diabetes who require improved glycemic management.
People who are obese or overweight, or who struggle to control their weight.
People with insulin resistance have not responded appropriately to alternative treatments.
However, the medication is not recommended for:
Pediatrics and pregnant female patients
Individuals with Type 1 diabetes
Individuals with a history of thyroid cancer or pancreatitis (MEN2 syndrome)
individuals with severe gastrointestinal conditions.
Dr. Arora emphasized to The indian Express that "Mounjaro is absolutely contraindicated in patients with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Type 2 (MEN2) syndrome."
Given that obesity and diabetes are major issues in india, Eli Lilly is in a strong position to benefit from the move ahead of competition from rival Novo Nordisk's weight-loss medication Wegovy, which has not yet reached indian shores. With Mounjaro's arrival, millions of people's medical care may change dramatically.
Mounjaro: Pricing And Market Potential
Approved by India's drug regulator, Mounjaro is delivered via a once-weekly injection with two price points:
₹3,500 ($40.54) per vial of 2.5 mg
₹4,375 ($50.67) per vial of 5 mg
At 5 mg, patients should anticipate monthly expenses of approximately ₹16,000 ($200), well less than the U.S. list price of $1,086.37 per month although actual U.S. costs to American patients differ with insurance coverage. Despite its cost-effectiveness, healthcare analysts project strong demand for Mounjaro because of its efficacy in glycemic control as well as in weight loss.
Mechanism of Action
"Glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) are two important hormones that Mount Jaro copies," Dr. Manisha Arora, director of Internal Medicine at CK Birla Hospital in Delhi, told The indian Express. The hormones prolong satiety by controlling blood sugar levels, decreasing appetite, and delaying digestion. By acting on both GLP-1 receptors, Mounjaro's dual mechanism may be more effective than Ozempic's (Semaglutide).
Side Effects
In The indian Express, Dr. Arora issued a warning that patients can experience gastrointestinal side effects: "Gastrointestinal issues like nausea, vomiting, diarrhea, and acid reflux are common side effects. Frequent diarrhea can occasionally result in acute renal damage and dehydration. She said that gallbladder-related problems like inflammation and gallstones could be brought on by abrupt weight loss.
Appropriate Patient Profile
According to what Dr. Arora told The indian Express, Mounjaro is recommended for:
Adults with type 2 diabetes who require improved glycemic management.
People who are obese or overweight, or who struggle to control their weight.
People with insulin resistance have not responded appropriately to alternative treatments.
However, the medication is not recommended for:
Pediatrics and pregnant female patients
Individuals with Type 1 diabetes
Individuals with a history of thyroid cancer or pancreatitis (MEN2 syndrome)
individuals with severe gastrointestinal conditions.
Dr. Arora emphasized to The indian Express that "Mounjaro is absolutely contraindicated in patients with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Type 2 (MEN2) syndrome."
click and follow Indiaherald WhatsApp channel